Invicol

Executive Summary

Invicol is a Berlin-based medtech startup (founded 2018) developing the BMProbe™, a minimally invasive device designed to isolate rare circulating cells—including Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs)—directly from a patient's vein. This in vivo approach aims to overcome limitations of conventional liquid biopsies by enriching target cells before downstream analysis, potentially enabling earlier cancer detection, personalized treatment selection, and real-time monitoring of disease progression or therapeutic response. The company’s technology targets both oncology and cardiovascular disease, addressing a critical need for non-invasive diagnostic and monitoring tools. Currently at the pre-clinical stage, Invicol has not disclosed funding details or valuation, but its innovative platform could capture significant interest from diagnostic partners and oncology-focused investors.

Upcoming Catalysts (preview)

• Q2 2026Completion of first-in-human study results40% success
• Q4 2026Strategic partnership with a cancer diagnostics company50% success
• Q3 2026Regulatory milestone: CE marking application for BMProbe™30% success